Evidence supporting the use of: Piracetam
For the health condition: Senility

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Piracetam is a nootropic agent belonging to the racetam family, first synthesized in the 1960s. Its primary mechanism is believed to involve modulation of neurotransmitters and enhancement of neuronal membrane fluidity, which may support cognitive processes. Piracetam has been studied in the context of cognitive decline associated with aging, often referred to as "senility" or age-related cognitive impairment. Several clinical trials from the 1970s to the early 2000s have evaluated piracetam for cognitive symptoms in elderly patients. Some studies suggested modest improvements in memory, attention, and global cognitive function compared with placebo, particularly in those with mild cognitive impairment or early dementia.

However, the quality and consistency of evidence are limited. Many trials were small, had methodological weaknesses, or yielded mixed results. A 2001 Cochrane review concluded that there was insufficient evidence to support the routine use of piracetam for dementia or cognitive impairment in the elderly, though some benefit was not entirely ruled out. More recent guidelines do not recommend piracetam for treating senility or dementia due to lack of convincing efficacy and regulatory approval in many countries has been withdrawn for this indication. Thus, while there is a scientific rationale and some historical clinical use, the strength of evidence supporting piracetam for senility is weak and not definitive.

More about Piracetam
More about Senility

Products containing Piracetam

We currently have no products on Vitabase that contain this ingredient.